Akeso Presents Positive Findings on Cadonilimab for Cervical Cancer
Akeso Biopharma (9926.HK) has announced significant progress in the treatment of cervical cancer through its Phase 3 clinical study involving cadonilimab, a PD-1/CTLA-4 bispecific antibody. The study, which is also recognized at the International Gynecologic Cancer Society annual meeting, displayed promising results in terms of progression-free survival (PFS) and overall survival (OS).
Overview of the COMPASSION-16 Study
The COMPASSION-16 study evaluated cadonilimab's effectiveness when used in combination with platinum-based chemotherapy and bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer. With a total of 445 participants, the focus was on demonstrating the benefits of cadonilimab versus traditional placebo treatments.
Key Study Outcomes
The key endpoints, progression-free survival (PFS) and overall survival (OS), showed remarkable outcomes. For patients receiving the cadonilimab regimen, OS remained unreached at the time of reporting, contrasting significantly with a median OS of 22.8 months observed in the control group. The 12-month OS rates indicated that 83.1% of the cadonilimab group remained alive, compared to 73.7% in the control group.
Benefits of Treatment with Cadonilimab
Results indicated that cadonilimab not only prolongs overall survival but also considerably decreases the risks associated with disease progression. The median PFS for the treatment group was 12.7 months, outperforming the control's 8.1 months, highlighting the regimen's superior efficacy.
Reduction in Mortality Risk
The findings demonstrated cadonilimab's potential to reduce the risk of death significantly, delivering a 50% reduction in mortality among patients who are not treated with bevacizumab. This is essential for addressing the clinical needs of patients who may not be eligible for additional therapies.
Effectiveness Across Patient Demographics
Notably, the cadonilimab regimen displayed efficacy across different PD-L1 expression levels. In cohorts with CPS lower than 1, the treatment was still associated with a 23% reduction in death risk. Furthermore, significant reductions of 31% and 32% were observed in patients with higher CPS expression, pointing to the antibody's broad applicability.
Antitumor Response and Safety Profile
The study yielded a high objective response rate (ORR) of 82.9% for the cadonilimab group versus 68.6% in the control group. The complete response rates were also promising, further showcasing the long-lasting benefits of cadonilimab with a median duration of response lasting significantly longer than that of the control.
Moreover, the safety profile of cadonilimab, particularly when administered with chemotherapy and bevacizumab, remained manageable without new adverse signals. These results are pivotal in reinforcing the potential for cadonilimab as a primary treatment option in the fight against cervical cancer.
Frequently Asked Questions
What is cadonilimab used for?
Cadonilimab is utilized for treating persistent, recurrent, or metastatic cervical cancer, showing promising clinical efficacy.
What were the main findings of the COMPASSION-16 study?
The study revealed significant improvements in overall survival and progression-free survival for patients using cadonilimab compared to traditional treatment methods.
How does cadonilimab compare to other treatments?
Cadonilimab offers a reduced mortality risk and increased effectiveness across varying levels of PD-L1 expression compared to conventional treatments.
What is the safety profile of cadonilimab?
Cadonilimab has demonstrated a manageable safety profile with no new safety signals during the study.
What are the implications of this study for cervical cancer treatment?
This study positions cadonilimab as a viable treatment option for cervical cancer and could significantly improve treatment protocols moving forward.
